HOME >> BIOLOGY >> NEWS
Targeted Genetics presents clinical data on E1A cancer gene therapy

Phase II data and summary of Phase I studies presented at ASCO

New Orleans, LA-May 22, 2000-Targeted Genetics Corporation (Nasdaq: TGEN) yesterday presented data from its clinical studies of tgDCC-E1A, the Company's lead cancer therapy, at the 36th American Society of Clinical Oncology Annual Meeting in New Orleans, Louisiana. Dr. Thomas C. Reynolds, Vice President, Clinical Affairs at Targeted Genetics, presented data from clinical trials of tgDCC-E1A in patients with head and neck cancer or ovarian cancer at a poster discussion session on the topic of Biologic Therapy for cancer. Preclinical data from studies of a systemic delivery formulation of E1A also were presented in the same poster.

Data from a recently completed Phase II study of tgDCC-E1A in recurrent head and neck squamous cell carcinoma (HNSCC) were presented in an abstract titled "Activity of E1A in Human Clinical Trials." The Phase II study evaluated tgDCC-E1A as single-agent therapy in 24 patients with recurrent HNSCC. Patients received 30ug DNA/cm3 of tumor via intratumoral injection daily for three days and then weekly for seven weeks. The most common side effect was pain at the injection site, and no serious adverse events related to tgDCC-E1A were reported. Of 20 evaluable patients, 45% showed objective responses or stabilization of their disease as assessed by CT analysis. A 5% complete response rate also was observed by the same criteria. Tumor response was determined as a function of tumor growth measured by physical exam and by two-dimensional and three-dimensional CT analysis.

"These data suggest that tgDCC-E1A is safe and will be useful in the treatment of head and neck cancer," said Dr. Reynolds. "Although patients in this study had very advanced disease, we were able to generate a 45% response rate using tgDCC-E1A as a single agent. Preclinical studies show that E1A can sensitize tumors to radiation and chemotherapy and we believe that comb
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
21-May-2000


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Targeted Genetics presents clinical data cancer gene therapy

(Date:6/17/2013)... may turn out to be just as important as what ... Michael,s Hospital. , The study, led by Dr. Nav ... poor eating habits in kids ages three to five and ... them at risk for cardiovascular disease later in life. , ... Journal today. , "We know that eating behaviours ...
(Date:6/17/2013)... D supplementation may help delay early onset of puberty ... were presented Monday at The Endocrine Society,s 95th Annual ... begins between the ages of 10 and 14. Boys ... years of age. Precocious puberty is diagnosed in girls ... in boys, it is diagnosed when these changes occur ...
(Date:6/17/2013)... are declining worldwide and a major cause is a ... a two-year study shows they can also die from ... tolerant carrier host that just spreads the disease. , ... experimental conditions, they found at least one strain of ... or a chytrid fungus, can be fatal to year-old ...
Breaking Biology News(10 mins):Poor eating behaviors may put preschoolers at risk for later health problems 2Vitamin D supplementation may delay precocious puberty in girls 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2
(Date:6/18/2013)... ALBANY, N.Y. , June 18, 2013 /PRNewswire/ ... that its Burlington, Mass. , ... U.S. Drug Enforcement Administration (DEA) registration to handle ... represents the DEA,s acknowledgement of Burlington,s ... inventory control and documentation. (Logo: ...
(Date:6/18/2013)... 2013 This webinar will examine ... and promotion, and review the basic FDA regulations ... to apply these principles through real world case ...     The fundamentals on FDA regulations and guidance related ...     Assessing traditional and newer forms of promotional ...
(Date:6/18/2013)... As a leading provider of telehealth ... release of their infographic - " 8 New ... goal was to leverage an information graphic to ... 3.0 and mHealth.The infographic features a list of ... the fitness industry in unimaginable ways; turning science ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 New user ... Saniclave 200 prevent the dangers of misuse and ... like knobs, analog pressure gauges, hot surfaces and complex ... or a new, modern autoclave, Revolutionary Science explains some ... water. Older autoclave designs will recycle dirty water. ...
Breaking Biology Technology:AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2How to Autoclave: Why the User Friendliness of the Saniclave 200 is So Important Today 2
Cached News: